检索结果-南通市图书馆

ymdd mutations in patients with chronic hepatitis B untreated with antiviral medicines

World Journal of Gastroenterology 2005年第6期11卷 867-870页

作者： Zhong-MinHuang Qi-WenHuang Ya-QinQin Yan-ZhuanHe Hou-JiQin Yiao-NanZhou XiangXu Mei-JinHuang DepartmentofInfectiousDiseases TheAffiliatedHospitalofYouJiangMedicalCollegeforNationalitiesBaise533000GuangxiZhuangAutonomousRegionChina

AIM: To polymerase P region (ymdd) mutations of hepatitis B virus gene (HBV DNA) in patients with chronic hepatitis B (CHB) untreated with antiviral medicines and to explore its correlation with pre-c-zone mutations, HBV genotypes and HBV DNA level, and to observe its curative ***: A total of 104 cases (38 cases in group of familial aggregation and 66 cases in group of non-familial aggregation) were randomly chosen from 226 patients with CHB who did not receive the treatment of lamivudine (LAM)and any other antivirus drugs within the last one *** serum ymdd mutations were detected by microcosmic nucleic acid and cross-nucleic acid quantitative determination,HBV genotypes by PCR-microcosmic nucleic acid crossELISA, HBV DNA quantitative determination and fluorescence ration PCR analysis, hepatitis B virus markers (HBVM) by ELISA. LAM was taken by 10 patients with ymdd mutations and its curative effect was ***: Twenty-eight cases (26.9%) had ymdd mutations, of them 11 cases (28.9%) were in familial aggregation group (38 cases) and 17 cases (25.8%) in nonfamilial aggregation group (66 cases) with no significant difference between the two groups. Twenty-seven point one percent (16/59) cases were positive for HBeAg ymdd mutations, and 26.7% (12/45) cases were negative for HBeAg and positive for anti-HBe. There was also no significant difference between the two groups. Different ymdd incidence rate existed in different HBV *** DNA level did not have a positive correlation with the incidence of ymdd mutations. LAM was effective for all patients with ***: Wild mutant strains in HBV and their incidence rate have no significant difference between familial aggregation and non-familial aggregation. It may have no significant relationship between ymdd mutations and pre-c-zone mutations. HBV DNA level may not have a positive correlation with ymdd mutations. LAM is clinically effective for CHB patients with ymdd mutations.

关键词： Hepatitis B virus Chronic hepatitis Genotypes ymdd mutation Lamivudine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatitis B virus genotypes and lamivudine resistance mutations in Jordan

引用

World Journal of Gastroenterology 2008年第47期14卷 7231-7234页

作者： Hani A Masaadeh Wail A Hayajneh Enayat A Alqudah Department of Pathology Faculty of MedicineJordan University of Science and TechnologyIrbid 22110Jordan Department of Pediatrics Faculty of MedicineJordan University of Science and TechnologyIrbid 22110Jordan Faculty of Applied Medical Sciences Jordan University of Science and TechnologyIrbid 21110Jordan

AIM:To investigate and identify prevalent hepatitis B virus(HBV) genotypes and to explore lamivudine-resistant mutations among treated and untreated patients in ***:A total of 107 cases with chronic hepatitis B were recruited from different medical centers in *** tests were preformed for all cases using a microparticle enzyme *** Genotyping was performed for 70 cases using Line probe genotyping *** ymdd mutations were explored for 20 cases(4 were lamivudine naive) using the INNO-LiPA HBV DR ***:Genotype D was the only detected genotype.A total of 6 ymdd mutations were detected in 5 treated patients(31%) while one mutation was detected in the naive *** percent of cases were positive for HBeAg and had statistically significant higher levels of serum ***:HBV genotype D appears to be the only circulating type in Jordanian *** ymdd mutations were detected in 31% of lamivudine-treated cases with similar patterns to those found in the *** also found a relatively low prevalence of HBeAg expression among examined cases(17%).Awareness of these serologic,genotypic and resistance patterns might help in the formulation of management plans and for predicting clinical *** larger scale studies are needed to confirm our results and to examine possible associations among clinical,serologic,and genetic patterns of HBV infections in Jordan.

关键词： Hepatitis B virus Genotypes Lamivudine ymdd mutation Jordan

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population

引用

World Journal of Gastroenterology 2005年第41期11卷 6525-6529页

作者： Zhong-Min Huang Qi-Wen Huang Ya-Qin Qin Chun-He Huang Hou-Ji Qin Yiao-Nan Zhou Xiang Xu Chun-Lei Lu Department of Infectious Diseases The Affiliated Hospital of Youjiang Medical College for Minority Nationalities Baise 533000 Guangxi Zhuang Autonomous Region China

AIM: To investigate the distribution of HBV genotypes and their ymdd mutations in Guangxi Zhuang population, China, and to study the relationship between HBV genotypes and clinical types of HB, ALT, HBV DNA, HBe system as well as the curative effect of Lamivudine (LAM) on hepatitis ***: A total of 156 cases were randomly chosen as study subjects from 317 patients with chronic hepatitis B (CHB). HBV genotypes were determined by PCR-microcosmic nucleic acid cross-ELISA. ymdd mutations were detected by microcosmic nucleic acid cross-nucleic acid quantitative determination. HBV DNA was detected by fluorescence ratio PCR *** was given to 81 cases and its curative effect was observed by measuring ALT, HBV DNA load, HBeAg, and HBeAg/HBeAb conversion ***: HBV genotypes B, C, D, and non-classified genotypes were found in Guangxi Zhuang *** for 25.6%, 47.4%, 58.3%, and 16.0%,respectively. Seventy-four cases were CD-, CB-, BD-mixed genotypes (47.7%). Forty-six (29.5%) cases had ymdd mutations. Genotype B was mostly found in mild and moderate CHB patients. Genotypes C, D and mixed genotype mostly occurred in severe CHB *** D and CD HBV-infected patients had higher ALT and HBV DNA than patients with other types of HBV infection. There was no significant difference among the genotypes in ymdd mutations, clinical types, ALT and HBV DNA level. Non-classified types geno had a significantly lower positive rate of HBeAg than other genotypes (x2= 12.841, P＜0.05). There was no significant difference in ALT recovery rate, HBV DNA load, HBeAg,and HBeAg/HBeAb conversion rate, 48 wk after LAM treatment between groups of genotypes D, CD, and nonclassified ***: Genotypes B, C, and D, non-classified and mixed genotype of HBV are identified in the Guangxi Zhuang population. Variations in genotypes are associated with clinical severity and serum ALT levels, but not with ymdd mutation or HBV DNA *** effects of LAM on c

关键词： Hepatitis B virus Chronic hepatitis Genotype ymdd mutation Lamivudine Zhuang nationality

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Lamivudine resistance in children with chronic hepatitis B

引用

World Journal of Hepatology 2015年第6期7卷 896-902页

作者： Erhun Kasirga Department of Pediatric Gastroenterology Celal Bayar University

Currently, although lamivudine(LAM) has a low genetic barrier, only interferon-alpha and LAM are available as a first-line treatment in children with chronic hepatitis B(CHB). LAM is a potent inhibitor of hepatitis B virusdeoxyribonucleic acid(HBV-DNA) polymerase replication by termination of the proviral HBV-DNA chain. LAM has a good safety and tolerability profile in CHB patients with hepatic decompensation. However, the main disadvantages of this HBV reverse transcriptase inhibitor are:(1) pre-existing covalently closed circular DNA cannot be eradicated by LAM, thus relapse after therapy withdrawal is frequent; and(2) although the longer LAMtreatment induced the higher seroconversion rate, the risk of viral resistance increased through the selection of ymdd(tyrosine, methionine, aspartate, aspartate) motif. Insufficient suppression of viral replication leads to the emergence of resistant strains that could result in virological breakthrough which is usually followed by biochemical breakthrough. Mutant strains affects additional resistance and cross resistance, leading to drug resistance in a significant number of CHB patients. In this case, efficacy of more powerful anti-viral agents with higher genetic barrier against development of resistance is diminished. Furthermore, strains that are resistant to LAM could bring about vaccine escape mutants, decreasing the efficacy of HBV vaccine. A more potent drug with a high genetic barrier to resistance needs to be approved as the first-line treatment option for CHB in children.

关键词： Children Chronic hepatitis B Lamivudine Lamivudine-resistant mutants ymdd mutation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：